May 13 (Reuters) - Allogene Therapeutics Inc:
* AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) ABSTRACT REPORTS INITIAL ALLO-501 ALPHA PHASE 1 DATA IN RELAPSED/REFRACTORY NON-HODGKIN LYMPHOMA
* ALLOGENE-ALLO-501 COMBINED WITH ALLO-647 BASED LYMPHODEPLETION REGIMEN WELL TOLERATED WITH NO DOSE-LIMITING TOXICITIES/EVIDENCE OF GRAFT-VERSUS-HOST DISEASE
* ALLOGENE THERAPEUTICS INC - EXPECTS TO INITIATE ENROLLMENT IN ALPHA2, A PHASE 1 TRIAL WITH ABBREVIATED DOSE ESCALATION OF ALLO-501A, IN Q2 2020 Source text for Eikon: Further company coverage:
